Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) have earned a consensus rating of “Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $40.00.
A number of brokerages recently issued reports on PRTK. BidaskClub cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Guggenheim initiated coverage on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They set a “buy” rating and a $44.00 target price for the company. Cantor Fitzgerald set a $50.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 17th. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th.
Shares of Paratek Pharmaceuticals (NASDAQ PRTK) traded up $0.05 on Monday, hitting $18.20. 267,245 shares of the stock traded hands, compared to its average volume of 372,681. Paratek Pharmaceuticals has a 12 month low of $13.95 and a 12 month high of $29.00. The company has a market capitalization of $508.53, a PE ratio of -4.88 and a beta of 0.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53.
Hedge funds have recently made changes to their positions in the company. Great West Life Assurance Co. Can purchased a new position in Paratek Pharmaceuticals during the third quarter valued at approximately $104,000. SG Americas Securities LLC bought a new stake in shares of Paratek Pharmaceuticals during the third quarter valued at approximately $123,000. Legal & General Group Plc raised its position in shares of Paratek Pharmaceuticals by 13.3% during the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after buying an additional 687 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at approximately $172,000. Finally, Citigroup Inc. raised its position in shares of Paratek Pharmaceuticals by 19,470.0% during the second quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 7,788 shares during the last quarter. Hedge funds and other institutional investors own 84.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/12/paratek-pharmaceuticals-inc-prtk-receives-42-71-consensus-price-target-from-brokerages.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.